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Adiponectin Inhibits Neutrophil Phagocytosis of
Escherichia coli by Inhibition of PKB and ERK 1/2 MAPK
Signalling and Mac-1 Activation
Alessandra Rossi, Janet Lord*
Medical Research Council Centre for Immune Regulation, School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom
Abstract
Full length adiponectin is a potent immune modulatory adipokine, impacting upon the actions of several immune cells.
Neutrophil oxidative burst has been shown to decrease in response to adiponectin, and we speculated that it could have
other effects on neutrophil function. Here we report that adiponectin reduces the phagocytic ability of human neutrophils,
decreasing significantly the ingestion of opsonised E. coli by these cells in whole blood (p,0.05) and as isolated neutrophils
(p,0.05). We then determined the mechanisms involved. We observed that the activation of Mac-1, the receptor engaged
in complement-mediated phagocytosis, was decreased by adiponectin in response to E. coli stimulation. Moreover,
treatment of neutrophils with adiponectin prior to incubation with E. coli significantly inhibited signalling through the PI3K/
PKB and ERK 1/2 pathways, with a parallel reduction of F-actin content. Studies with pharmacological inhibitors showed that
inhibition of PI3K/PKB, but not ERK 1/2 signalling was able to prevent the activation of Mac-1. In conclusion, we propose
that adiponectin negatively affects neutrophil phagocytosis, reducing the uptake of E. coli and inhibiting Mac-1 activation,
the latter by blockade of the PI3K/PKB signal pathway.
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Introduction
Adipose tissue is the main source of adipokines, circulating
molecules that like cytokines are engaged in regulating a variety of
physiological and pathological processes. Adiponectin is the most
abundant adipokine, reaching concentrations greater than 10 mg/
ml in the circulation [1]. Structurally, adiponectin belongs to the
C1q/Tumor Necrosis Factor (TNF) superfamily, with its C-
terminal domain sharing homology with the complement factor
C1q [2]. Different isoforms of adiponectin have been identified:
full-length adiponectin, which further oligomerises to form trimers
of low molecular weight, hexamers and polymers of high
molecular weight [3].
Adiponectin has aroused increasing interest because of its
insulin-sensitising [4,5], anti-atherosclerotic [6] and anti-inflam-
matory properties [7] and its levels have been shown to be
inversely correlated with obesity [8] and type 2 diabetes mellitus
[9,10]. Adiponectin appears to achieve many of its actions through
activation of AMP-activated protein kinase (AMPK), with
phosphorylation of AMPK shown to increase following treatment
with adiponectin in several cell types including endothelial cells,
peripheral blood mononuclear cells (PBMCs) [11] and phagocytes
[12]. In relation to its anti-inflammatory role, adiponectin prevents
lipopolysaccharide (LPS)-induced acute lung injury (ALI) in mice
by inhibiting the production of IL-6 by lung endothelial cells [13]
and protects against LPS-induced liver injury in obese mouse
models by diminishing TNF-a production [14]. In addition, it has
also been shown to inhibit NK cell cytotoxicity [15] and to induce
human monocytes to differentiate into alternative the anti-
inflammatory M2 macrophage phenotype [16]. Contradictory
results have been reported in relation to adiponectin effects on
macrophage phagocytosis [17,18] and dendritic cell function
[19,20].
Neutrophils are the most abundant immune cell population in
the blood, representing the first line of defence against microbial
pathogens and with a major pro-inflammatory role. These short-
lived cells migrate towards the site of infection where they
contribute to the removal and the killing of pathogens through the
processes of phagocytosis, degranulation and release of microbi-
cidal peptides, production of reactive oxygen species (ROS) and
generation of neutrophil extracellular traps (NETs) [21,22]. Both
neutrophil and monocyte ROS production in response to the
bacterial product fMLP are reduced by the addition of full-length
adiponectin, which inhibits NADPH oxidase activation by
decreasing the phosphorylation of the p47phox subunit [12]. In
contrast, globular adiponectin has been shown to enhance
phagocyte ROS production, favouring NADPH oxidase activation
via phosphorylation of the MAPK: ERK 1/2 and p38 [12].
Neutrophil phagocytosis is initiated by ligation of several
receptors, including cytokine receptors, pattern recognition
receptors (PRRs) such as Toll-like receptor 4 (TLR4), the opsonic
Fc-c receptors FccRI, FccRII and FccRIII (CD16), and the
complement receptors CR1 (CD35) and CR3 (CD11b/CD18),
alternatively called Mac-1 [23]. Mac-1 undergoes activation by
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conformational change in stimulated neutrophils thus achieving a
higher affinity and avidity towards its ligands [24]. Following
binding to neutrophil membranes, bacterial ingestion is associated
with intracellular signalling involving MAPK activation: both
ERK 1/2 and p38 MAPK are phosphorylated in response to
microbial challenge [25], and activation of the PI3K/PKB
pathway has also been shown to be fundamental for cytoskeletal
rearrangements during phagocytosis [26,27].
Despite the major pro-inflammatory role of neutrophils the
effect exerted by adiponectin on neutrophil phagocytosis has not
been investigated, therefore this study aimed to evaluate whether
this adipokine could influence the phagocytosis of the bacteria E.
coli and the mechanisms involved.
Results
Adiponectin inhibits neutrophil phagocytosis of E. coli
Pre-treating whole blood for one hour with a physiological dose
of adiponectin (10 mg/ml) resulted in a significant decrease in the
neutrophil phagocytic index for uptake of E. coli (p,0.05; Fig. 1A).
We then confirmed that adiponectin directly modulates neutrophil
phagocytosis, using isolated neutrophils in serum-free media pre-
incubated with adiponectin for one hour before the addition of E.
coli (40:1 ratio, E. coli:neutrophils), previously opsonised with
autologous serum. Figure 1B shows that adiponectin (0.1, 1 and
10 mg/ml) inhibited neutrophil phagocytosis in a dose-dependent
manner. The degree of inhibition was greater than that seen with
whole blood possibly due to the presence of adiponectin in the
blood. We also determined the stability of the adiponectin effect
over time and found the inhibition of phagocytosis was maintained
for up to 90 minutes (Figure 1C). Different bacteria to neutrophil
ratios (5:1, 20:1) were tested and the decrease in phagocytosis with
adiponectin was seen at all ratios (data not shown). We also
assessed the surface expression of the two receptors for
adiponectin, AdipoR1 and AdipoR2, in 10 donors and we
consistently found high expression of both receptors (Figure 1D
and E).
Adiponectin reduces Mac-1 activation and bacterial
binding to neutrophils
Neutrophils express a broad range of phagocytic receptors
which are necessary to promote the ingestion of opsonised
microbes. To delineate whether adiponectin could influence the
uptake of bacteria through the modulation of phagocytic receptors
the surface expression of CD16, CD11b and TLR4 on resting
neutrophils was assessed after a one hour treatment with
adiponectin. The expression of none of these receptors was
affected by adiponectin treatment (data not shown). Mac-1 is a
dimer of CD11b and CD18 and is a complement receptor that
undergoes activation by conformational change in stimulated
neutrophils [24]. Its activation was measured using a specific
antibody against the activation induced epitope of Mac-1 after
neutrophils were pre-incubated with adiponectin and stimulated
with opsonised E. coli for 90 minutes. Levels of activated Mac-1
(expressed as MFI, Figure 2A) and the percentage of cells bearing
active Mac-1 (Figure 2B) were both significantly decreased in the
presence of adiponectin. As the conformational change of Mac-1
leads to increased receptor affinity towards its ligands [24], we
hypothesized that the reduction in the phagocytosis mediated by
adiponectin may be due in part to decreased binding of bacteria to
Mac-1. Therefore, we evaluated the binding of FITC labelled E.
coli to the neutrophil surface at 4uC at 30, 60 and 90 minutes after
pre-incubation with adiponectin. The binding of bacteria was
significantly reduced by adiponectin at each time point (Figure 2C).
Adiponectin inhibits PKB and ERK signalling
The process of phagocytosis is accompanied by increased
activation of PI3K/PKB and MAPK signalling pathways. Hence
we evaluated the effect of adiponectin on phosphorylation of PKB,
ERK 1/2 and p38 MAPK by western blotting using antibodies
specific to the phosphorylated forms of these kinases. E. coli
stimulated neutrophils which were pre-treated with adiponectin
displayed significantly lower phosphorylation of both PKB and
ERK 1/2 compared to control stimulated neutrophils, though the
effect was consistently most marked for ERK 1/2 (Fig. 3A, B). p38
phosphorylation was not affected by adiponectin.
To confirm that PI3K/PKB and ERK 1/2 activation was
necessary to sustain neutrophil phagocytosis, we studied this
function after pharmacologically blocking these two pathways.
The inhibitors LY294002 (PI3K inhibitor) and PD98059 (an
inhibitor of MEKI which is directly upstream of ERK 1/2) were
added 30 minutes before initiation of the phagocytosis assay. The
inhibition of both PI3K/PKB and ERK1/2 pathways resulted in a
reduction in neutrophil phagocytosis (Fig. 3C) in a concentration
dependent manner and the efficacy of the two inhibitors was
confirmed by western blot (data not shown). The specificity of
LY294002 and PD98059 for PI3K and ERK 1/2 is very good and
has been reported previously with LY294002 only inhibiting
additionally casein kinase 2 even when used at 50mM [28,29]. The
concentrations employed here are also widely used [30–34].
As adiponectin signalling results in the activation of AMPK in a
variety of cell types, including phagocytes [12], we also evaluated
whether this kinase could contribute to decreased neutrophil
phagocytosis. We pre-incubated neutrophils with the AMPK
activator AICAR (1 mM) for 30 minutes prior to the addition of
E. coli but the treatment did not reduce neutrophil phagocytosis
(data not shown) therefore adiponectin is unlikely to act through
this factor to inhibit neutrophil phagocytosis.
Mac-1 activation depends on PI3K but not ERK 1/2
activation
As adiponectin inhibited both PI3K-PKB and ERK signalling
and also Mac-1 activation, we attempted to determine whether
these two pathways were involved in Mac-1 conformational
change in neutrophils stimulated with bacteria. Our results suggest
that PI3K, but not ERK 1/2, contributes to regulating the
activation of Mac-1 in response to bacterial stimulation, as pre-
treatment with LY294002 (Fig. 4A) but not with PD98059 (Fig. 4B)
caused a significant decrease in the activation of Mac-1.
Adiponectin inhibits the F-actin increase in response to E.
coli stimulation
Actin polymerisation is required for bacterial uptake [35]. The
extension of pseudopods is controlled by PI3K [26,27] and ERK
1/2 has also been shown recently to play a role in regulating
cytoskeletal modifications [36,37]. As we found a decrease in PKB
phosphorylation in the presence of adiponectin (Figure 3A), we
proposed that the reduction in PI3K and ERK 1/2 activation
could also have decreased F-actin generation in response to E. coli.
F-actin staining with FITC phalloidin confirmed that adiponectin
decreased actin polymerization after 5 minutes of stimulation with
unlabelled bacteria (Figure 5), indicating a lack of pseudopod
maturation and phagosome formation.
Complement C1q does not prevent adiponectin effects
on phagocytosis
The adiponectin C-terminal domain shares homology with the
serum complement protein C1q and the adiponectin-mediated
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inhibition of macrophage phagocytosis has been shown to be
blocked by the use of a C1qRp antibody [18]. We therefore
assessed whether inclusion of complement protein C1q protein
would be able to block the adiponectin effect on phagocytosis.
Neutrophils were pre-incubated with human serum C1q (at the
physiological concentration of 100 mg/ml [38]) in order to allow
binding to its receptors prior to the addition of adiponectin.
Figure 1. Adiponectin decreases neutrophil phagocytosis. Adiponectin was added to (A) whole blood (n = 10) at a final concentration of
10 mg/ml or (B) isolated human neutrophils (n$6) at different concentrations (0.1, 1 and 10 mg/ml) prior to addition of opsonized FITC labelled E. coli
and assessment of phagocytic index by flow cytometry. C. Time course of neutrophil phagocytosis (30, 60, 90 minutes) with and without the
presence of adiponectin (10 mg/ml). Data are mean 6 SEM and * indicates p,0.05, ** indicates p,0.02. D. Percentage of human neutrophils
expressing adiponectin receptors AdipoR1 and AdipoR2. The bar represents the mean value. E. Representative FACS plots are shown for
immunofluorescence staining for the adiponectin receptors AdipoR1 and AdipoR2.
doi:10.1371/journal.pone.0069108.g001
Figure 2. Adiponectin inhibits the activation of Mac-1 and the binding of E. coli to the neutrophil surface. Isolated neutrophils treated
with adiponectin for 1 hour and stimulated with opsonied E. coli were immunostained for the activated conformation of Mac-1. (A) Mac-1 expression
(MFI) and (B) the percentage of neutrophils expressing active Mac-1 were decreased by adiponectin. Data are mean 6 SEM (n= 7). C. The binding of
bacteria to the neutrophil cell surface was measured by flow cytometry following pre-treatment with adiponectin and after 30, 60 and 90 minutes of
incubation with opsonized FITC labeled E. coli at 4uC. FITC negative cells were considered unbound. Data are expressed as the percentage of cells
with no E.coli bound and are mean 6 SEM (n$7).
doi:10.1371/journal.pone.0069108.g002
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However, the addition of C1q did not prevent adiponectin-
mediated inhibition of neutrophil phagocytosis (Fig. 6).
Discussion
The process of phagocytosis is central to the anti-microbial
effects of neutrophils, representing the first step in the elimination
of bacteria and resolution of infection. Full-length adiponectin has
already been shown to impair neutrophil ability to kill pathogens
by reducing the generation of ROS [12]. Here we have
demonstrated that adiponectin also negatively affects neutrophil
phagocytic ability in a concentration dependent manner. The
inhibitory function of adiponectin was much greater on isolated
neutrophils than in whole blood, which is most likely due to the
presence of adiponectin in the blood, though we cannot exclude
Figure 3. Adiponectin reduces neutrophil phagocytosis by decreasing the phosphorylation of PKB and ERK 1/2 but not p38 in
response to E. coli. Neutrophils were pre-incubated with adiponectin and stimulated with opsonised E. coli for 10 minutes after which proteins
were extracted and analysed by western blotting. A. Representative western blots showing the effect of adiponectin on phosphorylation of PKB, ERK
1/2 and p38 MAPK induced by E. coli. B. Densitometric analysis of three separate experiments for the effect of adiponectin on phosphorylation of PKB,
ERK 1/2 and p38 MAPK, expressed as the ratio between the phosphorylated and unphosphorylated proteins. C. The PI3K inhibitor LY294002 and
MEK1 inhibitor PD98059 (10 mM and 50 mM) were added to neutrophils for 30 minutes prior to addition of opsonised FITC labeled E. coli and the
phagocytic index was measured by flow cytometry. Control samples were treated with the highest concentration of carrier (DMSO) used. Data are
mean 6 SEM (n= 5). * indicates p,0.05, ** indicates p,0.01, *** indicates p,0.001 for treated versus control cells.
doi:10.1371/journal.pone.0069108.g003
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that the possibility that in whole blood adiponectin’s effects are
modified by other serum factors or immune cells.
We found that adiponectin did not change the expression of the
phagocytic receptors CD11b, CD16 and TLR4 but it did
significantly reduce the activation of the complement receptor
Mac-1 in response to E. coli stimulation. Mac-1 binds to a range of
ligands, the most relevant for phagocytosis being the opsonin
iC3b. Accordingly, the binding of bacteria to the neutrophil
surface was decreased. Mac-1 has also been shown to be involved
in the engulfement of bacteria [39] and to enhance FccR-
mediated phagocytosis without affecting the binding [40,41],
hence Mac-1 reduced activation could also contribute to the
decreased uptake of opsonised E.coli.
In addition, we revealed that adiponectin inhibited the
phosphorylation of PKB and ERK 1/2 in response to bacterial
stimulation. PKB phosphorylation represents a downstream
measure of PI3K signalling, which sustains the phagocytic process
[26,27,42]. ERK 1/2 also has a crucial role in neutrophil
phagocytosis [37,43], its activation being both downstream and
independent of PI3K activation [27]. We were able to confirm
their involvement in neutrophil phagocytosis by using the
inhibitors LY29004 and PD98059. PD98059 treatment has been
shown to lead to activation of AMPK indirectly by increasing the
cellular AMP:ATP ratio [44]. However this should not contribute
Figure 4. PI3K inhibition reduces Mac-1 activation. A. The PI3K
inhibitor LY294002 and (B) the MEK1 inhibitor PD98059 (10 and 50 mM)
were added to neutrophils for 30 minutes before stimulating the cells
with opsonised E. coli. After 90 minutes the activation of Mac-1 was
assessed by flow cytometry. Unstimulated and control E. coli stimulated
samples were incubated with the highest concentration of carrier
(DMSO) used. Data are mean 6 SEM (n= 6). ** indicates p,0.01, ***
p,0.001.
doi:10.1371/journal.pone.0069108.g004 Figure 5. Adiponectin decreases actin polymerization in
response to E. coli stimulation. A. Neutrophils were pre-incubated
with adiponectin and stimulated with E. coli for 5 minutes, after which
F-actin content was evaluated by staining with FITC phalloidin. Samples
were analyzed by flow cytometry; data are mean 6 SEM (n= 7). *
indicates p,0.05. B. Representative images of F-actin in unstimulated
and E. coli stimulated neutrophils with and without pre-treatment with
adiponectin.
doi:10.1371/journal.pone.0069108.g005
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to decreased phagocytic ability as direct activation of this AMPK
did not affect phagocytosis.
We also determined that the conformational change of Mac-1
was dependent on PI3K but not ERK 1/2 activation. Previous
studies have shown that Mac-1 activation was mediated by
cytoskeletal rearrangements [45] and the intracytoplasmic domain
of CD18 is phosphorylated in stimulated neutrophils, contributing
to the conformational rearrangement of Mac-1 [46]. The PI3K
inhibitor LY29004 had a greater effect on neutrophil phagocytosis
than it did on Mac-1 activation, suggesting that PI3K is involved
in multiple aspects of the phagocytic process. For example, PI3K
has also been shown to be indispensable for the correct closure of
phagosomes [47].
ERKI 1/2 has been shown to be indispensable for phagocytosis
of Francisella tularensis, acting downstream of the tyrosine kinase
Syk, whose function is crucial for cytoskeletal rearrangements [37].
Importantly ERK 1/2, together with PI3K and other kinases,
phosphorylates cortactin, a monomeric protein involved in actin
polymerisation and lamellipodia formation [36]. Consistent with
the reduced activation of PI3K and ERK 1/2, we observed a
strong reduction in the content of F-actin in response to bacterial
stimulation suggesting that adiponectin treatment inhibits the
uptake of E. coli by blockage of both of these signal pathways.
AMPK is the main kinase previously reported to be activated by
adiponectin [11,12], however its activation does not mediate the
decrease in phagocytosis induced by adiponectin, as AICAR
treatment did not inhibit phagocytosis. This conclusion is
supported by a previous report that showed AICAR actually
increased neutrophil phagocytosis [48], though we did not see any
enhancement of phagocytosis at the dose used here.
Adiponectin might also have inhibited neutrophil phagocytosis
through its C-terminal C1q domain, which has been shown to act
in an antagonistic manner in macrophages by Yokota and
colleagues [18]. C1q is a serum complement factor whose main
receptor is C1qRp, but it has been proposed to bind to other
phagocytic receptors expressed by neutrophils, particularly CR1
[49]. To check whether adiponectin could decrease neutrophil
phagocytosis by blocking bacterial binding to these receptors
through its C1q-homologous domain, we pre-incubated the cells
with a physiological concentration of C1q before the addition of
adiponectin and before performing the phagocytosis assay, but we
did not observe any improvement in neutrophil phagocytosis.
Other groups have shown enhanced phagocytosis of apoptotic
bodies mediated by C1q in human macrophages [17] and
monocytic cell lines [17,50], suggesting that C1q influences
phagocytosis in a cell-specific manner.
In conclusion, these data demonstrate for the first time that
adiponectin decreases neutrophil ability to phagocytose E. coli, a
result observed both in whole blood and in isolated neutrophils. In
Figure 7, we propose that adiponectin exerts its effect by
decreasing the binding of bacteria to neutrophils through
suppression of Mac-1 activation and both the bacterial binding
and uptake are mediated by blockage of PI3K and ERK K
signaling. These data add weight to the literature highlighting an
immune modulatory role for adiponectin and importantly indicate
that this could help to explain the increased incidence of infections
seen in situations of raised circulating adiponectin, such as old age
[51,52]. The data are more difficult to interpret in the case of
obesity, a complex condition which is characterized by higher risk
of infection [53] but lower levels of adiponectin [8].
Materials and Methods
Ethics statement
The study was approved by the Birmingham East North and
Solihull Research Ethics Committee (09/H1206/48) and all
subjects gave their written informed consent before taking part
in the study.
Reagents and antibodies
Human recombinant full length adiponectin generated in
HEK293 cells (HMW isoforms and hexamers, as specified in the
datasheet) was purchased from Enzo Life Sciences (Farmingdale,
NY, USA), with contamination from LPS certified to be less than
0.1 EU/mg purified protein. To ensure no artefactual effects from
LPS contamination, Polymyxin B (10 mg/ml) (Millipore, MA) was
added to the cells 30 min before treatment with adiponectin.
Percoll, RPMI 1640 medium, L-glutamine, penicillin-streptomy-
cin, bovine serum albumin (BSA), dimethyl sulfoxide (DMSO),
human complement factor C1q, FITC phalloidin, protease
inhibitor cocktail and all buffers and salt solutions were purchased
from Sigma-Aldrich (Poole, UK). The MEK-1/ERK inhibitor
PD98059 was from Cell Signaling Technology (Beverly, MA), the
PI3K inhibitor LY29004 was from Millipore and the AMPK
activator AICAR was purchased from Enzo Life Sciences.
Unconjugated antibodies against AdipoR1 and AdipoR2 were
from Phoenix Pharmaceuticals (Burlingame, CA), the unconju-
gated mouse anti-human CD11b (clone 2LPM19c), FITC
conjugated CD16 (clone DJ130c) and isotype antibody FITC-
conjugated mouse IgG1k were obtained from Dako (Ely, UK).
Figure 6. Adiponectin-mediated inhibition of neutrophil
phagocytosis is not rescued by complement factor C1q. C1q
(100 mg/ml) was added to neutrophils 15 minutes before the addition
of adiponectin to saturate C1q receptors and phagocytosis of E. coli was
then measured. Data are mean 6 SEM (n= 6).
doi:10.1371/journal.pone.0069108.g006
Figure 7. Proposed model for adiponectin inhibition of
neutrophil phagocytosis.
doi:10.1371/journal.pone.0069108.g007
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FITC conjugated goat anti-rabbit secondary antibody was
purchased from Southern Biotech (Birmingham, AL) and FITC
conjugated goat anti-mouse secondary antibody was from Sigma-
Aldrich. The anti-human CD284 (TLR4) (clone HTA125), the
FITC conjugated mouse anti-human Mac-1 (activation epitope;
clone CBRM1/5) and the APC-conjugated mouse IgG2a were
obtained from eBiosciences (San Diego, CA). Antibodies against
phosphorylated ERK1/2 (Thr202/Tyr204), total ERK 1/2,
phosphorylated p38 MAPK (Thr180/Tyr182) and total PKB
were purchased from Cell Signaling Technology, the antibody
against total p38 MAPK was from Santa Cruz Biotechnology
(Santa Cruz, CA) and the antibody against phosphorylated PKB
(Ser473) was purchased from Millipore. Stabilized E. coli, FITC
labelled and unlabelled, were obtained from Glycotope-Biotech-
nology GmbH (Heidelberg, Germany).
Neutrophil isolation and treatment
Heparinised peripheral blood was obtained from healthy
human donors and neutrophils were isolated by density centrifu-
gation as previously described [54]. Briefly, 2% dextran solution
was added to peripheral blood, the leukocyte layer was collected
and neutrophils were purified by discontinuous Percoll density
gradient centrifugation under endotoxin-free conditions. The
purity of isolated neutrophils was determined by Giemsa staining
(Diff-Quick, Baxter Healthcare, UK) and light microscopy and
was routinely greater than 97%. For all studies neutrophils were
resuspended in RPMI-1640 medium containing 2mM L-gluta-
mine, 100 U/ml penicillin and 100 mg/ml streptomycin.
To evaluate whether adiponectin could influence neutrophil
phagocytosis, either whole blood or isolated neutrophils were
incubated with adiponectin or vehicle (sterile distilled water) for
one hour prior to the assay. The protein kinase inhibitors/
activators PD98059 (10 and 50 mM), LY294002 (10 and 50 mM)
and AICAR (1 mM) were added to isolated neutrophils 30 min-
utes before the addition of the bacteria, whereas the complement
factor C1q (100 mg/ml) was pre-incubated 15 minutes before
addition of adiponectin.
Measurement of neutrophil phagocytosis and binding of
E. coli
Phagocytosis was assessed using the commercial kit PhagotestTM
(Glycotope-Biotechnology GmbH, Germany) in whole blood
according to the manufacturer’s instructions: blood was incubated
with E. coli for 10 minutes, erythrocytes were lysed and samples
were analyzed by flow cytometry to distinguish uptake by
neutrophils from that by monocytes. Using the same reagents
provided by the kit but with further optimisation, phagocytosis by
isolated neutrophils was also examined. Briefly, FITC labeled E.
coli were opsonised with 10% autologous serum in Hanks balanced
salt solution (HBSS) at 37uC for 30 minutes, after which they were
washed in PBS and resuspended in medium at the same initial
volume. All experiments with isolated neutrophils were performed
in the absence of serum to exclude interference by adiponectin in
the serum. 50 ml of neutrophils at 56106/ml were dispensed into a
96-well round bottomed plate (Sarstedt, UK) and E. coli were
added (1:40, 1:20 or 1:5 ratio between neutrophils and bacteria).
The suspensions were incubated for 30, 60 or 90 minutes at 37uC,
after which the assay was stopped by adding 100 ml of quenching
solution to extinguish the FITC fluorescence of surface bound
bacteria. A negative control was represented by the same
suspension incubated at 0uC. The samples were transferred to
FACS tubes and analyzed by flow cytometry (BD Accuri C6 Flow
Cytometer, Accuri Cytometers Inc, Ann Arbor, MI) and the
phagocytic index was determined. The phagocytic index was
calculated as the percentage of the cells having ingested bacteria
(FITC positive cells), multiplied by the mean fluorescence intensity
(MFI) of the FITC positive population and divided by 100.
Cytospins of the suspensions were also obtained and visualized
using a LEICA DMI 6000 B microscope x63 objective (Leica
Microsystems, UK).
To evaluate the binding of bacteria to neutrophil walls,
suspensions were incubated at 4uC for 30, 60 and 90 minutes
without final addition of quenching solution; samples were
analyzed by flow cytometry, FITC negative cells were considered
not to have bound bacteria.
Measurement of surface receptor expression
Surface expression of adiponectin receptors (AdipoR1 and
AdipoR2) and CD11b was measured by indirect immunofluores-
cence staining and negative controls consisted of staining with
appropriate secondary antibodies alone. Adiponectin receptors
were detected with unconjugated rabbit anti-human AdipoR1 and
AdipoR2 (5 mg/ml) and CD11b expression was measured with
mouse anti-CD11b (10 mg/ml). Nonspecific binding sites were
blocked by addition of goat serum for 5 minutes before adding the
secondary FITC conjugated goat anti-rabbit (2.5 mg/ml) or goat
anti-mouse (5 mg/ml) antibodies. Surface expression of the
activated form of Mac-1, CD16 and TLR4 were assessed by
direct immunofluorescence staining (10 mg/ml for anti-Mac-1 and
anti-TLR4, 4 mg/ml for anti-CD16); concentration-matched
isotype antibodies mouse FITC IgG1 and mouse APC IgG2a
were used as negative controls for Mac-1, CD16 and TLR4.
Samples were analyzed by flow cytometry.
Measurement of PI3K-PKB, ERK and p38 MAPK activation
Neutrophils were stimulated with unlabeled, opsonised E. coli
for 10 minutes and spun at 4000 rpm for 4 minutes (MSE
microcentrifuge) prior to resuspension in lysis buffer (20 mM
MOPS, 50 mM NaF, 50 mM b-glycerophosphate , 50 mM
Na3VO4, 1% Triton X-100, 1 mM DTT, 1 mM AEBSF and
1% protease inhibitor cocktail). Lysis of neutrophils was performed
on ice for 30 minutes with occasional vortexing. The lysate was
centrifuged at 13,000 rpm for 1 minute (MSE microcentrifuge)
and the supernatant collected and combined with an equal volume
of SDS-PAGE sample buffer (125 mM HCl pH 6.8, 5% glycerol,
2% SDS, 1% b-mercaptoethanol, 0.003% bromophenol blue).
Lysates were boiled for 10 minutes, separated by SDS-PAGE and
blotted onto PVDF membranes. Non-specific protein binding was
blocked using 5% BSA. Membranes were incubated with primary
antibodies to total PKB (1:1000), phosphorylated PKB (1:1000),
total ERK 1/2 (1:1000), phosphorylated ERK 1/2 (1:1000), total
p38 MAPK (1:500), phosphorylated p38 MAPK (1:1000),
overnight at 4uC and with appropriate secondary antibodies
(ECLTM anti-rabbit or anti-mouse IgG; GE Healthcare, Sweden)
for 1 hour at room temperature. Proteins were visualized by ECL
according to manufacturer’s instructions (GeneFlow, UK). Den-
sitometric analyses were performed using Image J software.
Measurement of actin polymerisation
Actin polymerisation was assessed by measuring F actin levels.
Neutrophils were stimulated with unlabeled, opsonised E. coli for
5 minutes, after which they were subjected to fixation and
permeabilisation using a Fix and PermH kit (Life technologies,
CA) according to the manufacturer’s instructions. Neutrophils
were incubated with FITC labeled phalloidin (1 mg/ml) for
30 minutes. After washing in PBS, samples were analysed by flow
cytometry. Cytospins were also obtained and nuclei were stained
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with DAPI (Life Technologies) and cells were visualised using a
LEICA DMI 6000 B microscope and x63 objective.
Statistical analyses
Data were analysed using GraphPad Prism 4 software
(GraphPad Software Ltd). Two-tailed paired Student’s t-test was
used to compare paired samples and repeated measures ANOVA
was used to analyse more than two groups of matched samples,
followed by Tukey’s multiple comparison test. Results are
expressed as mean 6 standard error of the mean (SEM). A p
value of less than 0.05 was accepted as significant.
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